Filtered By:
Condition: Heart Attack
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 1021 results found since Jan 2013.
Effects of statins on outcomes in Hispanic patients with COVID-19
The Hispanic population is regarded among those who are at greater risk of adverse prognoses due to higher rates of diabetes and obesity in the USA during the COVID-19 pandemic. Statin medications are speculated to help treat the infection by decreasing inflammation caused by COVID-19. In this retrospective, observational study, outcomes of statin use were assessed among Hispanic patients with COVID-19 by screening all patients hospitalized between March, 2020 and March, 2021 at a tertiary care hospital in El Paso, Texas, resulting in a total of 1039 patients. The patients were categorized into a group of either being on s...
Source: Journal of Investigative Medicine - December 1, 2022 Category: Research Authors: Khalafi, S., Evans, J., Lumbreras, T., Tiula, K., Helmsdoerfer, K., Dwivedi, A. K., Dihowm, F. Tags: COVID-19 Original research Source Type: research
Predictive values of coronary artery calcium and arterial stiffness for long-term cardiovascular events in patients with stable coronary artery disease
CONCLUSIONS: A CAC score ≥100 or a CAVI ≥ 9.0 predicts the long-term occurrence of MACEs in both asymptomatic and symptomatic patients with stable CAD. These two noninvasive tests can be used as screening tools to guide treatment for the prevention of future CV events.PMID:36448219 | DOI:10.1002/clc.23955
Source: Atherosclerosis - November 30, 2022 Category: Cardiology Authors: Thosaphol Limpijankit Sutipong Jongjirasiri Krissada Meemook Nattawut Unwanatham Ammarin Thakkinstian Jiraporn Laothamatas Source Type: research
Statin therapy for primary prevention in men: What is the role for coronary artery calcium?
Statin therapy is widely prescribed for patients with established ASCVD (secondary prevention). Meta-analysis of randomized clinical trials (RCTs) show conclusively that statins substantially reduce recurrent major ASCVD events (myocardial infarction and stroke)1. More problematic is use of statins for patients without ASCVD (primary prevention). RCTs clearly demonstrate that statins can lower ASCVD for primary prevention in patients at higher risk for future vascular events2-4; however, the number needed to treat (NNT) to prevent one ASCVD event is much higher for primary prevention than for secondary prevention.
Source: Journal of Clinical Lipidology - November 23, 2022 Category: Lipidology Authors: Scott M. Grundy, Jijia Wong, Gloria L. Vega Source Type: research
World Heart Federation Cholesterol Roadmap 2022
CONCLUSIONS: The adverse effects of LDL-cholesterol and apo B containing lipoprotein exposure are cumulative and result in ASCVD. These are preventable by implementation of different strategies, aimed at efficiently tackling atherosclerosis at different stages throughout the human life-course. Preventive strategies should therefore be updated to implement health policy, lifestyle changes and when needed pharmacotherapies earlier with investment in, and a shift in focus towards, early preventive strategies that preserve cardiovascular health rather than treat the consequences of ASCVD.PMID:36382159 | PMC:PMC9562775 | DOI:10.5334/gh.1154
Source: Atherosclerosis - November 16, 2022 Category: Cardiology Authors: Kausik K Ray Brian A Ference Tania S éverin Dirk Blom Stephen J Nicholls Mariko H Shiba Wael Almahmeed Rodrigo Alonso Magdalena Daccord Marat Ezhov Rosa Fern ández Olmo Piotr Jankowski Fernando Lanas Roopa Mehta Raman Puri Nathan D Wong David Wood Dong Source Type: research
Study Protocol and Baseline Characteristics of Randomized Trial for Evaluating Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid: RESPECT-EPA, The Combination of a Randomized Control Trial and an Observational Biomarker Study
CONCLUSIONS: After this study is completed, we will have further evidence on whether a highly purified EPA is effective in reducing cardiovascular events for secondary prevention or not, as well as whether if EPA/AA ratio is a predictor for future cardiovascular events.PMID:36372250 | DOI:10.1016/j.ahj.2022.11.008
Source: Cancer Control - November 13, 2022 Category: Cancer & Oncology Authors: Yuji Nishizaki Katsumi Miyauchi Hiroshi Iwata Teruo Inoue Atsushi Hirayama Kazuo Kimura Yukio Ozaki Toyoaki Murohara Kenji Ueshima Yoshihiro Kuwabara Sachiko Tanaka-Mizuno Naotake Yanagisawa Tosiya Sato Hiroyuki Daida Source Type: research
How People With Diabetes Can Lower Stroke Risk
After spending nearly two decades trying to manage her Type 2 diabetes, Agnes Czuchlewski landed in the emergency room in 2015, with news that she’d just experienced a heart attack. She also learned that she had metabolic syndrome, a cluster of conditions that includes diabetes but also brings higher risk of heart disease and stroke.
“Because I needed to lose quite a bit of weight when I was first diagnosed, I was focused on the number I saw on the scale, and then on my blood-sugar numbers,” recalls Czuchlewski, 68, who lives in New York City. “I didn’t realize other numbers came into play, li...
Source: TIME: Health - November 10, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized Disease healthscienceclimate Source Type: news
What to Know About Diabetes and the Risk of Silent Heart Attacks
At first it seemed like a routine call—something the paramedics had dealt with countless times before. A man in his mid-50s was having a heart attack, and his physician had called for emergency support. But when the paramedics arrived, the physician pulled them aside and told them something peculiar: the man had no cardiovascular symptoms whatsoever.
The man had come to his doctor’s office because he’d woken early the previous morning sweating and with a sharp pain in his left wrist. These symptoms had quickly subsided and he’d gone back to sleep. Later, after going about his day, he’d visited...
Source: TIME: Health - November 4, 2022 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate heart health Source Type: news
Lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: A prospective cohort study
ConclusionsLp(a) levels increased in half of statin-treated patients with first AIS. Creatinine and AST were positively associated with the percent change of Lp(a) levels. Lp(a) is a determinant of residual vascular risk and the change of Lp(a) is positively associated with the risk of recurrent vascular events in these patients.
Source: Frontiers in Neurology - November 3, 2022 Category: Neurology Source Type: research
Platelet Redox Imbalance in Hypercholesterolemia: A Big Problem for a Small Cell
Int J Mol Sci. 2022 Sep 28;23(19):11446. doi: 10.3390/ijms231911446.ABSTRACTThe imbalance between reactive oxygen species (ROS) synthesis and their scavenging by anti-oxidant defences is the common soil of many disorders, including hypercholesterolemia. Platelets, the smallest blood cells, are deeply involved in the pathophysiology of occlusive arterial thrombi associated with myocardial infarction and stroke. A great deal of evidence shows that both increased intraplatelet ROS synthesis and impaired ROS neutralization are implicated in the thrombotic process. Hypercholesterolemia is recognized as cause of atherosclerosis,...
Source: Atherosclerosis - October 14, 2022 Category: Cardiology Authors: Alessandro Morotti Cristina Barale Elena Melchionda Isabella Russo Source Type: research
The Effects of a Perindopril-Based Regimen in Relation to Statin Use on the Outcomes of Patients with Vascular Disease: a Combined Analysis of the ADVANCE, EUROPA, and PROGRESS Trials
ConclusionOur data suggest that the treatment benefits of a perindopril-based regimen in patients with vascular disease are independent of statin use.
Source: Cardiovascular Drugs and Therapy - October 4, 2022 Category: Cardiology Source Type: research
Higher mortality in acute coronary syndrome patients without standard modifiable risk factors: Results from a global meta-analysis of 1,285,722 patients
CONCLUSION: In this study level meta-analysis, SMuRF-less ACS patients demonstrate higher mortality compared with patients with at least one traditional atherosclerotic risk factor. Underuse of guideline-directed medical therapy amongst SMuRF-less patients is concerning. Unraveling novel risk factors amongst SMuRF-less individuals is the next important step.SUMMARY: Standard modifiable cardiovascular risk factors (SMuRF), comprising diabetes mellitus, hyperlipidemia, hypertension, and smoking, are often used for risk stratification in acute coronary syndrome (ACS). Recent studies showed an increasing proportion of SMuRF-le...
Source: Atherosclerosis - September 30, 2022 Category: Cardiology Authors: Gwyneth Kong Yip Han Chin Bryan Chong Rachel Sze Jen Goh Oliver Zi Hern Lim Cheng Han Ng Mark Muthiah Roger Foo Stephen T Vernon Poay Huan Loh Mark Y Chan Nicholas W S Chew Gemma A Figtree Source Type: research
Yield of Dual Therapy With Statin and Ezetimibe in the Treat Stroke to Target Trial
CONCLUSIONS: In the TST trial (Treat Stroke to Target), targeting an LDL cholesterol of < 70 mg/dL with a combination of statin and ezetimibe compared with 100±10 mg/dL consistently reduced the risk of subsequent stroke.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT01252875. URL: clinicaltrialsregister.eu; Unique identifier: EUDRACT2009-A01280-57.PMID:36154103 | DOI:10.1161/STROKEAHA.122.039728
Source: Atherosclerosis - September 26, 2022 Category: Cardiology Authors: Pierre Amarenco Jong S Kim Julien Labreuche Hugo Charles Maurice Giroud Byung-Chul Lee Philippa C Lavall ée Marie-H élène Mahagne Elena Meseguer Norbert Nighoghossian Philippe Gabriel Steg Éric Vicaut Eric Bruckert Treat Stroke to Target Investigators Source Type: research
